Table 4 Relationship between PAC, recurrence and immunohistochemical reactivity for myosin IIA and vimentin

From: Proteomic analysis of stage I primary lung adenocarcinoma aimed at individualisation of postoperative therapy

 

M(−)V(−)

M(−)V(+) or M(+)V(−)

M(+)V(+)

ND

(A) Sample set A (n=24) derived from the same cases as those subjected to LC-MS/MS

U0R0

5

2

0

0

U1R0

2

3

0

1

U0R1

0

2

4

0

U1R1

0

0

5

0

(B) Sample set B (n=90) for validation by immunohistochemical analysis

 U0R0

6

11

5

0

 U1R0

3

12

12

0*

 U0R1

0

6

11

0

 U1R1

0

10

14

0

  1. M=expression of myosin IIA; ND=not done; U0R0=patients without PAC showing no recurrence within 5 years after surgery; U0R1=patients without PAC showing recurrence within 5 years after surgery; U1R0=patients who received PAC with uracil–tegafur and showed no recurrence within 5 years after surgery; U1R1=patients who received PAC with uracil–tegafur and showed recurrence within 5 years after surgery; V=expression of vimentin.
  2. *Statistically significant difference between U0R0 and U1R1 was detected (P=0.008).
Back to article page